Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Gimatecan · 4 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Gimatecan | EXPERIMENTAL | - |
| LBQ707 | EXPERIMENTAL | - |
| Daily times five schedule | EXPERIMENTAL | - |
| Continuous schedule, twice daily | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Gimatecan | DRUG | - |
Inclusion criteria * Patients with histological or cytological confirmed advanced solid tumors, which progressed despite standard therapy or for whom no standard therapy exists * Life expectancy of at least 3 months * No dysfunction of bone marrow * No major impairment of renal and hepatic function...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Gimatecan is an investigational small molecule being studied for the treatment of solid tumors and advanced solid tumors. It is in Phase 1 clinical development and has not been approved by regulatory authorities. Clinical trials have evaluated it in adult patients with advanced solid tumors, including Japanese patients.
Gimatecan is being developed by Novartis AG, which is publicly traded under the ticker symbol NVS. The company has sponsored Phase 1 clinical trials of this investigational oncology drug in patients with solid tumors and advanced solid tumors.
Gimatecan is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. All completed trials for Gimatecan were Phase 1 dose-escalation studies, and no active trials are currently listed.
Gimatecan has been studied in three completed Phase 1 trials: NCT00410358, a dose escalation in Japanese patients with advanced solid tumors; NCT00420485, a dose-escalation study in adult patients with solid tumors; and NCT00441610, an extension trial in Japanese patients. These trials enrolled a total of 120 patients.
Yes, Gimatecan is also known as LBQ707. One clinical trial, NCT00487058, is titled 'A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors,' confirming that LBQ707 and Gimatecan refer to the same drug.